| Symbol
| FASN
| contributors: mct/npt - updated : 27-05-2017
|
| HGNC name
| fatty acid synthase
|
| HGNC id
| 3594
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| constitutional
|
|
| --over
|
| |
in adipose tissue is linked to visceral fat accumulation, impaired insulin sensitivity, increased circulating fasting insulin, and leading to the development of obesity and type 2 diabetes (Berndt 2007) | | tumoral
|
|
| --over
|
| |
in several neoplasms including colorectal adenomas and carcinomas (Kearney 2009) | | tumoral
|
|
| --over
|
| |
in prostate carcinoma (Migita 2009) | | tumoral
|
|
| --over
|
|
in uterine leiomyomata  | | constitutional
|
| deletion
|
|
| |
hindered the development and induced the premature involution of the lactating mammary gland and significantly decreased medium- and long-chain fatty acids and total fatty acid contents in the milk | | constitutional
|
|
| --over
|
| |
in the hearts of humans with end stage cardiomyopathy | |
| Susceptibility
|
to severe epileptic encephalopathies |
| Variant & Polymorphism
other
| causative role of FASN mutations in severe epileptic encephalopathies |
| 
|
Candidate gene
| Marker
| may serve as a new diagnostic marker of NAFLD (nonalcoholic fatty liver disease) | |
circulating FASN is a biomarker of overnutrition-induced insulin resistance that could provide diagnostic and prognostic advantages by providing insights on the individualized metabolic stress | | Therapy target
| | |
|
| System | Type | Disorder | Pubmed |
|---|
| cancer | eye | | |
| promising strategy in Retinoblastoma therapy | | cancer | endocrine | thyroid | |
| FASN and activated AKT1 pathway may be a potential target for therapeutic intervention for the treatment of papillary thyroid cancers | | immunology | infectious | | |
| suitable as a therapeutic target in coxsackievirus B3 (CVB3)-induced diseases | | cancer | digestive | colon | |
| inhibition of FASN upstream of VEGFA and other angiogenic pathways can be a novel therapeutic strategy to prevent or inhibit metastasis in colorectal cancer | | digestive | liver | | |
| therapeutic target for the progression of NAFLD (nonalcoholic fatty liver disease) |
| |
|
| conditional deletion of Fasn in mouse neural stem and progenitor cells (NSPCs) impairs adult neurogenesis |